Form 4: Biogen CFO Robin Kramer Reports Stock Transactions

Biogen CFO Robin Kramer reported multiple transactions involving common stock and restricted stock units, primarily related to RSU vesting and tax withholdings.

Summary

• Biogen Inc.'s Chief Financial Officer, Robin Kramer, reported multiple transactions on February 6, 2026, involving the company's common stock and restricted stock units (RSUs).
• Kramer acquired a total of 5,003 shares of common stock (789 + 703 + 3,511) through the vesting of RSUs, with an exercise price of $0 per share.
• Concurrently, Kramer disposed of a total of 1,543 shares of common stock (273 + 207 + 1,063) at a price of $201.18 per share, primarily to cover tax obligations associated with the RSU vesting.
• Following these transactions, Kramer's direct beneficial ownership of Biogen common stock stands at 11,471.7483 shares.
• The RSUs vested in installments, with grant dates ranging from February 8, 2023, to February 6, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, reflecting routine executive compensation activities rather than a discretionary investment decision or a significant change in company fundamentals.

Positives

• The vesting of restricted stock units represents the realization of previously granted compensation for the Chief Financial Officer.

Negatives

• The disposition of shares to cover tax obligations is a standard practice associated with RSU vesting and does not indicate a negative outlook on the company.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that these transactions are routine compensation-related events for a senior executive, reflecting the vesting of previously granted equity awards rather than discretionary open-market purchases or sales based on new strategic insights.

Comparison to Industry Standards

• The reported transactions, involving the vesting of restricted stock units and subsequent sales for tax withholding, are standard practices for executive compensation across various industries, including the biotechnology sector. This aligns with typical equity compensation structures seen at comparable companies like Amgen Inc. or Gilead Sciences, Inc., where executives receive performance-based or time-based equity awards that vest over several years.

Stakeholder Impact

• Shareholders: Minimal direct impact as these are routine compensation events and do not reflect a change in company strategy or performance.
• Employees: No direct impact mentioned.

Next Steps

• Future installments of the restricted stock units granted on February 8, 2023, are expected to vest.
• Future installments of the restricted stock units granted on February 7, 2024, are expected to vest.
• Future installments of the restricted stock units granted on February 6, 2025, are expected to vest.

Key Dates

Recommendation

The Form 4 filing details routine insider transactions related to the vesting of restricted stock units and subsequent tax-related sales by Biogen's CFO. These transactions are part of standard executive compensation and do not indicate a change in the company's fundamental outlook or warrant a change in investment recommendation based solely on this filing.

Keywords

Biogen, BIIB, Form 4, Insider Trading, Stock Transactions, CFO, Robin Kramer, Restricted Stock Units, RSU, Common Stock